Olga M. Koteshkova
Research Subjects
Olga M. Koteshkova has a total of 71 co-authors. Here are the top co-authors by number of shared publications:
- Michail Borisovich Antsiferov
Endocrinological Dispensary; Russian Medical Academy of Continuous Professional Education
15 shared publications Antsiferova D.M. Antsiferova
5 shared publicationsM.B. Antsiferov Antsiferov
5 shared publications- Nikolay A. Demidov
Scherbinskaya City Hospital
5 shared publications - Gagik Radikovich Galstyan
Endocrinology Research Centre
4 shared publications Moscow Russian Medical Academy Of Continuous Professional Education
4 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Sechenov University in National Health Care (Russia)
- Vol. 7 (2) , 39-51
Diabetes mellitus before and after kidney transplantation: five-year outcomes and organizational priorities in the late post-transplant period
Aim. To assess temporal trends in the proportion of diabetic kidney disease as the primary cause of end-stage kidney disease among kidney transplant recipients, compare 5-year clinical outcomes according to diabetes mellitus status, and identify priorities for long-term post-transplant care. Materials and methods. This single-center retrospective observational study included 2,146 adult kidney transplant recipients who underwent kidney transplantation between 1989 and 2018; temporal trends were examined across five consecutive 6-year periods. Five-year outcomes were assessed in 851 recipients who underwent isolated kidney transplantation between 2013 and 2018. Recipients with pre-existing diabetes mellitus were compared with those without diabetes at transplantation. Additional analyses included four phenotypic groups: type 1 diabetes mellitus, type 2 diabetes mellitus, post-transplant diabetes mellitus, and no diabetes mellitus. Results. The proportion of diabetic kidney disease as the primary cause of end-stage kidney disease increased from 0% in 1989–1994 to 13.8% in 2007–2012 and was 10.8% in 2013–2018. A significant increasing trend was observed for type 2 diabetes mellitus (p < 0.001). Pre-existing diabetes mellitus was present in 88 recipients (10.3%). Five-year all-cause mortality was higher among recipients with pre-existing diabetes mellitus than among those without diabetes at transplantation (30.7% vs. 8.0%; relative risk, 3.84; 95% confidence interval, 2.58–5.70). Composite cardiovascular events were also more frequent (12.5% vs. 4.8%; relative risk, 2.58; 95% confidence interval, 1.36–4.87). The incidence of the composite kidney outcome was similar between groups (8.0% vs. 7.6%; p = 0.906). Post-transplant diabetes mellitus developed in 80 of 763 recipients without diabetes at transplantation (10.5%). The incidence of de novo malignancy and infection-related mortality did not differ significantly between groups. A functioning kidney allograft was present at death in 87.5% of deceased recipients. Conclusion. Pre-existing diabetes mellitus was associated with higher all-cause mortality and a greater burden of cardiovascular events, while kidney outcomes were similar. These findings support a nephrologist-coordinated multidisciplinary long-term follow-up model integrating endocrinology and cardiovascular care, systematic screening for post-transplant diabetes mellitus, infection prevention, and cancer surveillance.
- 19 October 2026
- Published by Sechenov University in National Health Care (Russia)
- Vol. 7 (2) , 39-51
Open AccessDiabetes mellitus before and after kidney transplantation: five-year outcomes and organizational priorities in the late post-transplant period
Aim. To assess temporal trends in the proportion of diabetic kidney disease as the primary cause of end-stage kidney disease among kidney transplant recipients, compare 5-year clinical outcomes according to diabetes mellitus status, and identify priorities for long-term post-transplant care. Materials and methods. This single-center retrospective observational study included 2,146 adult kidney transplant recipients who underwent kidney transplantation between 1989 and 2018; temporal trends were examined across five consecutive 6-year periods. Five-year outcomes were assessed in 851 recipients who underwent isolated kidney transplantation between 2013 and 2018. Recipients with pre-existing diabetes mellitus were compared with those without diabetes at transplantation. Additional analyses included four phenotypic groups: type 1 diabetes mellitus, type 2 diabetes mellitus, post-transplant diabetes mellitus, and no diabetes mellitus. Results. The proportion of diabetic kidney disease as the primary cause of end-stage kidney disease increased from 0% in 1989–1994 to 13.8% in 2007–2012 and was 10.8% in 2013–2018. A significant increasing trend was observed for type 2 diabetes mellitus (p < 0.001). Pre-existing diabetes mellitus was present in 88 recipients (10.3%). Five-year all-cause mortality was higher among recipients with pre-existing diabetes mellitus than among those without diabetes at transplantation (30.7% vs. 8.0%; relative risk, 3.84; 95% confidence interval, 2.58–5.70). Composite cardiovascular events were also more frequent (12.5% vs. 4.8%; relative risk, 2.58; 95% confidence interval, 1.36–4.87). The incidence of the composite kidney outcome was similar between groups (8.0% vs. 7.6%; p = 0.906). Post-transplant diabetes mellitus developed in 80 of 763 recipients without diabetes at transplantation (10.5%). The incidence of de novo malignancy and infection-related mortality did not differ significantly between groups. A functioning kidney allograft was present at death in 87.5% of deceased recipients. Conclusion. Pre-existing diabetes mellitus was associated with higher all-cause mortality and a greater burden of cardiovascular events, while kidney outcomes were similar. These findings support a nephrologist-coordinated multidisciplinary long-term follow-up model integrating endocrinology and cardiovascular care, systematic screening for post-transplant diabetes mellitus, infection prevention, and cancer surveillance.
- 22 May 2026
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 72 (3) , 36-43
Safety Management of Incretin-Based Obesity Therapy: Expert Consensus on the Use of Semaglutide and Tirzepatide
On December 3, 2025, a meeting of the expert working group was held in Moscow. The discussion focused on the safety and personalized use of tirzepatide (Tirzetta®) and semaglutide (Velgia® eco) in patients with overweight and obesity. Following the meeting, a consensus position was developed on the optimal use of incretin receptor agonists in real-world clinical practice.
- 22 May 2026
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 72 (3) , 36-43
Safety Management of Incretin-Based Obesity Therapy: Expert Consensus on the Use of Semaglutide and Tirzepatide
On December 3, 2025, a meeting of the expert working group was held in Moscow. The discussion focused on the safety and personalized use of tirzepatide (Tirzetta®) and semaglutide (Velgia® eco) in patients with overweight and obesity. Following the meeting, a consensus position was developed on the optimal use of incretin receptor agonists in real-world clinical practice.
- 11 February 2026
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 29 (1) , 40-49
Evaluation of the effectiveness of semaglutide in providing metabolic control and correction of insulin resistance in patients with type 2 diabetes mellitus in real clinical practice
RELEVANCE. Type 2 diabetes mellitus (DM2) is closely related to obesity and insulin resistance (IR). Semaglutide, glucagon-like peptide-1 receptor agonist, exhibits pronounced effects on glycemic control and body weight. However, data on its effect on various surrogate IR indices in routine practice are limited. AIM. To evaluate the effect of semaglutide (Semavic®) on metabolic control and IR in patients with DM2 and obesity who did not achieve the target values of carbohydrate metabolism on metformin monotherapy. MATERIALS AND METHODS. The prospective study included 31 patients aged 40–65 years with DM2, BMI 30.0–39.9 kg/m 2 and HbA 1c 7.0–9.0% on metformin treatment; 28 patients completed a 24-week follow-up. Anthropometric parameters, bioimpedance body composition, HbA 1c , fasting glycemia, insulin, C-peptide, free fatty acids were evaluated. HOMA-IR, QUICKI, TyG, Adipo-IR indices, C peptide/insulin molar ratio were calculated. RESULTS. After 24 weeks of semaglutide therapy, there was a significant decrease in body weight (median -8.2% or 8.58 kg), BMI, waist circumference and fat mass as well as an improvement in carbohydrate metabolism: HbA 1c had decreased from 7.63% to 6.25%, 85.7% of patients reached HbA 1c CONCLUSIONS. Semaglutide in patients with DM2 and obesity in real clinical practice provides a significant reduction of body weight, improves glycemic control and leads to multicomponent reduction of IR with a favorable safety profile.
- 11 February 2026
- Published by Endocrinology Research Centre in Diabetes mellitus
- Vol. 29 (1) , 40-49
Evaluation of the effectiveness of semaglutide in providing metabolic control and correction of insulin resistance in patients with type 2 diabetes mellitus in real clinical practice
RELEVANCE. Type 2 diabetes mellitus (DM2) is closely related to obesity and insulin resistance (IR). Semaglutide, glucagon-like peptide-1 receptor agonist, exhibits pronounced effects on glycemic control and body weight. However, data on its effect on various surrogate IR indices in routine practice are limited. AIM. To evaluate the effect of semaglutide (Semavic®) on metabolic control and IR in patients with DM2 and obesity who did not achieve the target values of carbohydrate metabolism on metformin monotherapy. MATERIALS AND METHODS. The prospective study included 31 patients aged 40–65 years with DM2, BMI 30.0–39.9 kg/m 2 and HbA 1c 7.0–9.0% on metformin treatment; 28 patients completed a 24-week follow-up. Anthropometric parameters, bioimpedance body composition, HbA 1c , fasting glycemia, insulin, C-peptide, free fatty acids were evaluated. HOMA-IR, QUICKI, TyG, Adipo-IR indices, C peptide/insulin molar ratio were calculated. RESULTS. After 24 weeks of semaglutide therapy, there was a significant decrease in body weight (median -8.2% or 8.58 kg), BMI, waist circumference and fat mass as well as an improvement in carbohydrate metabolism: HbA 1c had decreased from 7.63% to 6.25%, 85.7% of patients reached HbA 1c CONCLUSIONS. Semaglutide in patients with DM2 and obesity in real clinical practice provides a significant reduction of body weight, improves glycemic control and leads to multicomponent reduction of IR with a favorable safety profile.
- 19 December 2025
- Published by Bionika Media in Pharmateca
- Vol. 8_2025
Advantages of GLP-1 receptor agonist therapy in comorbid patients with type 2 diabetes mellitus
- 19 December 2025
- Published by Bionika Media in Pharmateca
- Vol. 8_2025
Advantages of GLP-1 receptor agonist therapy in comorbid patients with type 2 diabetes mellitus
- Open Access
- 2 December 2025
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 71 (5) , 19-30
A personalized, evidence-based approach to obesity therapy using clinical algorithms: semaglutide or tirzepatide
On June 26, 2025, a meeting of the expert working group was held in Moscow. The discussion focused on the personalized approach of tirzepatide («Tirzetta®») and semaglutide («Velgia Eco®») in patients with excess body weight, obesity, and type 2 diabetes. Following the meeting, the objective was set to develop a consensus-based algorithm for prescribing these drugs to ensure their effective use in Russian clinical practice.
- 2 December 2025
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 71 (5) , 19-30
Open AccessA personalized, evidence-based approach to obesity therapy using clinical algorithms: semaglutide or tirzepatide
On June 26, 2025, a meeting of the expert working group was held in Moscow. The discussion focused on the personalized approach of tirzepatide («Tirzetta®») and semaglutide («Velgia Eco®») in patients with excess body weight, obesity, and type 2 diabetes. Following the meeting, the objective was set to develop a consensus-based algorithm for prescribing these drugs to ensure their effective use in Russian clinical practice.
- 20 November 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 16,p. 161-168
Have we done everything possible for a patient with type 2 diabetes mellitus combined with obesity?
Treatment of comorbid patients with type 2 diabetes mellitus (T2DM) is a serious challenge in modern endocrinology. For patients with T2DM, it is essential not only to achieve target carbohydrate metabolism parameters (hemoglobin HA1c, fasting and postprandial plasma glucose), but also to lose weight, improve blood lipid profiles and blood pressure, and ameliorate comorbid pathologies, one of which is metabolically associated fatty liver disease (MAFLD). This can be achieved using semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA). Currently, semaglutide leads in this class of drugs in terms of its impact on hypoglycemic and hyperglycemic ranges, lipid profile, body weight, and blood pressure, as well as its effectiveness in improving liver structure in patients with MAFLD. Multicenter clinical trials demonstrated its evident cardioprotective, nephroprotective, and hepatoprotective effects, as well as a significant reduction in the risk of development and progression of microvascular and macrovascular complications. This article presents a clinical case of the use of the domestic drug Semavic (semaglutide, Geropharm LLC) in a patient with long-standing type 2 diabetes, concomitant alimentary-constitutional obesity class II, and hepatic steatosis. The patient received metformin monotherapy. Due to failure to achieve target carbohydrate metabolism parameters, Semavic therapy was intensified (1 mg once weekly). The results demonstrated the high efficacy and safety of dual therapy with metformin combined with semaglutide in real-world settings. The clinical use of the domestic GLP-1RA will increase the treatment efficacy and improve the quality of life in patients with type 2 diabetes.
- 20 November 2025
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 16,p. 161-168
Have we done everything possible for a patient with type 2 diabetes mellitus combined with obesity?
Treatment of comorbid patients with type 2 diabetes mellitus (T2DM) is a serious challenge in modern endocrinology. For patients with T2DM, it is essential not only to achieve target carbohydrate metabolism parameters (hemoglobin HA1c, fasting and postprandial plasma glucose), but also to lose weight, improve blood lipid profiles and blood pressure, and ameliorate comorbid pathologies, one of which is metabolically associated fatty liver disease (MAFLD). This can be achieved using semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA). Currently, semaglutide leads in this class of drugs in terms of its impact on hypoglycemic and hyperglycemic ranges, lipid profile, body weight, and blood pressure, as well as its effectiveness in improving liver structure in patients with MAFLD. Multicenter clinical trials demonstrated its evident cardioprotective, nephroprotective, and hepatoprotective effects, as well as a significant reduction in the risk of development and progression of microvascular and macrovascular complications. This article presents a clinical case of the use of the domestic drug Semavic (semaglutide, Geropharm LLC) in a patient with long-standing type 2 diabetes, concomitant alimentary-constitutional obesity class II, and hepatic steatosis. The patient received metformin monotherapy. Due to failure to achieve target carbohydrate metabolism parameters, Semavic therapy was intensified (1 mg once weekly). The results demonstrated the high efficacy and safety of dual therapy with metformin combined with semaglutide in real-world settings. The clinical use of the domestic GLP-1RA will increase the treatment efficacy and improve the quality of life in patients with type 2 diabetes.
- Open Access
- 23 October 2025
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 65 (9) , 10-18
Efficacy and Safety of Sglt-2 Inhibitors In Renal Allograft Recipients: an Open-Label, Single-Center Prospective Study
Aim To evaluate the safety and efficacy of sodium-glucose cotransporter-2 inhibitor (SGLT-2i) inhibitor therapy in kidney transplant recipients (KTRs) with and without post-transplant diabetes mellitus (PTDM). Material and methods KTRs (n=2146, with PTDM n=303, or 14%) who had undergone transplantation more than one year ago, with stable graft function (estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m2), after excluding patients with combined kidney and pancreas transplantation (n=57), type 1 diabetes mellitus (DM) (n=124), and type 2 DM diagnosed before kidney allotransplantation (KAT) (n=74), were prescribed SGLT-2i (empagliflozin 25 mg/day or dapagliflozin 10 mg/day; n=107), the rest of the KTRs (n=1784) did not receive SGLT-2i. After pseudo-randomization, two groups were formed and included in an open, single-center prospective study: an experimental group with SGLT-2i (n=78; with PTDM n=45) and a control group, without SGLT-2i (n=78; n=45 with PTDM). The groups were comparable in the PTDM duration and the period from KAT to inclusion in the study, as well as in clinical characteristics, including gender, age, history of acute myocardial infarction (AMI) before KAT, levels of glycated hemoglobin (HbA1c), systolic blood pressure (SBP) and diastolic blood pressure (DBP), GFR, microalbuminuria (MAU), blood uric acid concentration, blood lipid profile (total cholesterol (TC), low-density lipoproteins (LDL)), basal blood concentration (C0) of calcineurin inhibitors (CNI), and therapy with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), statins, and metformin (p >0.05). Results The relative risk (RR) of all-cause death in the experimental group was reduced by 60% compared with the control group (RR 0.40; 95% confidence interval (CI) 0.17-0.98 vs. RR 2.44; 95% CI 1.01-5.86; p=0.04). The RR of adverse coronary outcomes in the experimental group was reduced by 75% compared with the control group (RR 0.25; 95% CI 0.06-0.89 vs. 4.0; 95% CI 1.11-14.42; p=0.03). The RR of adverse renal outcomes in the experimental group was reduced by 72% compared with the control group (RR 0.28; 95% CI 0.09-0.85 vs. 3.50; 95% CI 1.16-10.49; p=0.02). In addition, in the experimental group, compared to the control group, the GFR decline was slower (-1.29±0.763 ml/min/1.73 m2/year vs. -3.33±0.767 ml/min/1.73 m2/year; p=0.047). Also, a pronounced advantage in the dynamic decline in GFR was observed throughout the entire study period (-3.10±1.73 ml/min/1.73 m2 vs. -7.87±1.87 ml/min/1.73 m2; p=0.040). Conclusion SGLT2i effectively reduce cardiovascular and renal mortality, the risk of adverse renal and coronary outcomes, and slow the progression of chronic kidney disease in KTRs, regardless of the presence of PTDM. A large-scale study evaluating the efficacy of SGLT2i in KTRs is warranted to formulate appropriate clinical recommendations.
- 23 October 2025
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 65 (9) , 10-18
Open AccessEfficacy and Safety of Sglt-2 Inhibitors In Renal Allograft Recipients: an Open-Label, Single-Center Prospective Study
Aim To evaluate the safety and efficacy of sodium-glucose cotransporter-2 inhibitor (SGLT-2i) inhibitor therapy in kidney transplant recipients (KTRs) with and without post-transplant diabetes mellitus (PTDM). Material and methods KTRs (n=2146, with PTDM n=303, or 14%) who had undergone transplantation more than one year ago, with stable graft function (estimated glomerular filtration rate (eGFR) >30 ml/min/1.73 m2), after excluding patients with combined kidney and pancreas transplantation (n=57), type 1 diabetes mellitus (DM) (n=124), and type 2 DM diagnosed before kidney allotransplantation (KAT) (n=74), were prescribed SGLT-2i (empagliflozin 25 mg/day or dapagliflozin 10 mg/day; n=107), the rest of the KTRs (n=1784) did not receive SGLT-2i. After pseudo-randomization, two groups were formed and included in an open, single-center prospective study: an experimental group with SGLT-2i (n=78; with PTDM n=45) and a control group, without SGLT-2i (n=78; n=45 with PTDM). The groups were comparable in the PTDM duration and the period from KAT to inclusion in the study, as well as in clinical characteristics, including gender, age, history of acute myocardial infarction (AMI) before KAT, levels of glycated hemoglobin (HbA1c), systolic blood pressure (SBP) and diastolic blood pressure (DBP), GFR, microalbuminuria (MAU), blood uric acid concentration, blood lipid profile (total cholesterol (TC), low-density lipoproteins (LDL)), basal blood concentration (C0) of calcineurin inhibitors (CNI), and therapy with angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), statins, and metformin (p >0.05). Results The relative risk (RR) of all-cause death in the experimental group was reduced by 60% compared with the control group (RR 0.40; 95% confidence interval (CI) 0.17-0.98 vs. RR 2.44; 95% CI 1.01-5.86; p=0.04). The RR of adverse coronary outcomes in the experimental group was reduced by 75% compared with the control group (RR 0.25; 95% CI 0.06-0.89 vs. 4.0; 95% CI 1.11-14.42; p=0.03). The RR of adverse renal outcomes in the experimental group was reduced by 72% compared with the control group (RR 0.28; 95% CI 0.09-0.85 vs. 3.50; 95% CI 1.16-10.49; p=0.02). In addition, in the experimental group, compared to the control group, the GFR decline was slower (-1.29±0.763 ml/min/1.73 m2/year vs. -3.33±0.767 ml/min/1.73 m2/year; p=0.047). Also, a pronounced advantage in the dynamic decline in GFR was observed throughout the entire study period (-3.10±1.73 ml/min/1.73 m2 vs. -7.87±1.87 ml/min/1.73 m2; p=0.040). Conclusion SGLT2i effectively reduce cardiovascular and renal mortality, the risk of adverse renal and coronary outcomes, and slow the progression of chronic kidney disease in KTRs, regardless of the presence of PTDM. A large-scale study evaluating the efficacy of SGLT2i in KTRs is warranted to formulate appropriate clinical recommendations.
- 25 April 2025
- Published by Bionika Media in Pharmateca
- Vol. 2_2025
Can a glucometer with an intelligent mobile application become an alternative to continuous glycemic monitoring?
- 25 April 2025
- Published by Bionika Media in Pharmateca
- Vol. 2_2025
Can a glucometer with an intelligent mobile application become an alternative to continuous glycemic monitoring?
- Open Access
- 20 February 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (1) , 35-45
Risk factors for new-onset diabetes after transplantation in kidney transplant recipients: own data and meta-analysis
Aim. To compare risk factors for new-onset diabetes after transplantation (NODAT) among renal transplant recipients (RTRs) from 1989 to 2018 in the City Clinical Hospital №52, with a systematic analysis of published studies on this topic. Materials and methods. In a 30-year (1989–2018) retrospective study, we found statistically significant differences in age, gender, polycystic kidney disease, cadaveric kidney, cyclosporine, i-mTOR, and steroids between two groups of recipients with and without NODAT. Patients with NODAT were older, more male, more likely to have polycystic kidney disease and deceased donor kidneys, and more likely to be treated with cyclosporine, i-mTOR, and steroids (p0.05). We conducted a meta-analysis to evaluate the impact of these indicators on the development of NODAT. MEDLINE, Scopus, and the Cochrane Central Register of Controlled Trials were searched for eligible case-control studies of risk factors for NODAT in RTRs published between 1990 and 2019. Meta-analysis of proportions was performed using the Freeman–Tukey transformation to calculate weighted summary proportions from a fixed and random effects model. Results. A total of 13 case-control studies were included in the meta-analysis. Of the total 849 studies found, 13 were included in the systematic review and meta-analysis, including ours, with a total of n=6797 RTRs, of which n=1305 patients with NODAT and n=5492 without NODAT. A wide range of data was recorded for the analysis of the incidence of NODAT (6.5–50.7%), with an average of 17.9% (fixed model) or 24.3% (random model). The proportion of NODAT recorded in the Russian registry of the City Clinical Hospital №52 was lower (11.5%), however, the data in the analyzed studies were highly heterogeneous: I2=98.14%, 95% CI: from 97.61 to 98.55, p0.0001, Begg's test (p=0.05) and Egger's test (p=0.01) do not exclude the presence of publication bias in this case. Data on NODAT risk factors were less heterogeneous. This meta-analysis showed that age, polycystic kidney disease, i-mTOR and steroid therapy were associated with NODAT, whereas gender, calcineurin inhibitor use, and cadaveric kidney were not. There was no evidence of selection bias in any of the cases. Conclusion. Risk factors for NODAT in kidney transplant recipients include older age, polycystic kidney disease, i-mTOR and steroid therapy, which initiate a state of insulin resistance. To reduce the risk of NODAT, the possibility of modifying immunosuppression regimens and the use of drugs that reduce insulin resistance and have a nephroprotective effect in RTRs should be considered. Therefore, randomized studies are needed to evaluate SGLT2 inhibitor in RTRs.
- 20 February 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (1) , 35-45
Open AccessRisk factors for new-onset diabetes after transplantation in kidney transplant recipients: own data and meta-analysis
Aim. To compare risk factors for new-onset diabetes after transplantation (NODAT) among renal transplant recipients (RTRs) from 1989 to 2018 in the City Clinical Hospital №52, with a systematic analysis of published studies on this topic. Materials and methods. In a 30-year (1989–2018) retrospective study, we found statistically significant differences in age, gender, polycystic kidney disease, cadaveric kidney, cyclosporine, i-mTOR, and steroids between two groups of recipients with and without NODAT. Patients with NODAT were older, more male, more likely to have polycystic kidney disease and deceased donor kidneys, and more likely to be treated with cyclosporine, i-mTOR, and steroids (p0.05). We conducted a meta-analysis to evaluate the impact of these indicators on the development of NODAT. MEDLINE, Scopus, and the Cochrane Central Register of Controlled Trials were searched for eligible case-control studies of risk factors for NODAT in RTRs published between 1990 and 2019. Meta-analysis of proportions was performed using the Freeman–Tukey transformation to calculate weighted summary proportions from a fixed and random effects model. Results. A total of 13 case-control studies were included in the meta-analysis. Of the total 849 studies found, 13 were included in the systematic review and meta-analysis, including ours, with a total of n=6797 RTRs, of which n=1305 patients with NODAT and n=5492 without NODAT. A wide range of data was recorded for the analysis of the incidence of NODAT (6.5–50.7%), with an average of 17.9% (fixed model) or 24.3% (random model). The proportion of NODAT recorded in the Russian registry of the City Clinical Hospital №52 was lower (11.5%), however, the data in the analyzed studies were highly heterogeneous: I2=98.14%, 95% CI: from 97.61 to 98.55, p0.0001, Begg's test (p=0.05) and Egger's test (p=0.01) do not exclude the presence of publication bias in this case. Data on NODAT risk factors were less heterogeneous. This meta-analysis showed that age, polycystic kidney disease, i-mTOR and steroid therapy were associated with NODAT, whereas gender, calcineurin inhibitor use, and cadaveric kidney were not. There was no evidence of selection bias in any of the cases. Conclusion. Risk factors for NODAT in kidney transplant recipients include older age, polycystic kidney disease, i-mTOR and steroid therapy, which initiate a state of insulin resistance. To reduce the risk of NODAT, the possibility of modifying immunosuppression regimens and the use of drugs that reduce insulin resistance and have a nephroprotective effect in RTRs should be considered. Therefore, randomized studies are needed to evaluate SGLT2 inhibitor in RTRs.